FDA Approves Unknown Drug — HIKMA

HIKMA has received approval for the generic version of the undisclosed substance, effective September 18, 2026, positioning the company to capitalize on the upcoming U.S. market launch despite the pending patent challenges. The approval broadens HIKMA’s product portfolio and offers a significant revenue opportunity as consumers and payors seek affordable alternatives to the brand-name therapy.